This Phase I trial is enrolling 18 participants with syringomyelia to evaluate the safety and efficacy of spinal injection of molecules derived from human umbilical cord blood stem cells. These molecules are thought to improve nerve cell signaling. Syringomyelia is a condition in which a fluid-filled cavity forms within the spinal cord, which can damage spinal cord tissue and lead to pain or sensory loss. If included, participants will receive monthly injections into the spinal canal for three months, with escalating dose levels evaluated sequentially for safety. Final assessment of safety will be performed after 1 year.
Type
Details
- Participants will receive monthly injections of extracellular vesicles derived from human umbilical cord blood mesenchymal stem cells into the spinal canal for three months, with escalating dose levels evaluated sequentially for safety. - These extracellular vesicles (tiny particles) are thought to improve nerve cell signaling. - Syringomyelia is a condition in which a fluid-filled cavity forms within the spinal cord, which can damage spinal cord tissue and lead to pain or sensory loss. - Final assessment of safety will be performed after 1 year.
Main benefits
General health
Additional benefits
Arm/hand function
Sensory function
Standing/walking/mobility
Good to know: Potential benefits are defined as outcomes that are being measured during and/or after the trial.
Wings for Life has proudly initiated, led and funded the new version of the SCI Trials Finder website. Wings for Life aims to find a cure for spinal cord injuries. The not-for-profit foundation funds world-class scientific research and clinical trials around the globe.
Learn moreWings for Life has proudly initiated, led and funded the new version of the SCI Trials Finder website. Wings for Life aims to find a cure for spinal cord injuries. The not-for-profit foundation funds world-class scientific research and clinical trials around the globe.
Learn more